In February, researchers from MIT and Takeda Pharmaceuticals joined together to celebrate the official launch of the MIT-Takeda Program. The MIT-Takeda Program aims to fuel the development and application of artificial intelligence (AI) capabilities to benefit human health and drug development. Centered within the Abdul Latif Jameel Clinic for Machine Learning in Health (Jameel Clinic), the program brings together the MIT School of Engineering and Takeda Pharmaceuticals, to combine knowledge and address challenges of mutual interest.
Following a competitive proposal process, nine inaugural research projects were selected. MIT.nano Associate Director Brian Anthony is collaborating on one of these projects, "Machine learning for image-based liver phenotyping and drug discovery."